Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Alembic (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Alembic, is an angiotensin II receptor blocker (ARB) presented as a fixed‑dose combination tablet for oral use. It is employed to manage hypertension in adults, often when monotherapy does not achieve target blood pressure.

GNH USA supplies Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Alembic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and calcium‑channel pathways to lower blood pressure. - Hypertension: provides combined blockade of angiotensin II receptors, calcium‑channel mediated vasoconstriction, and diuresis to achieve better blood‑pressure control. - High‑risk cardiovascular patients: helps reach guideline‑recommended blood‑pressure targets when single‑agent therapy is insufficient. - Resistant hypertension: adds complementary mechanisms to overcome inadequate response to monotherapy.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially after the first dose. - Fatigue: general feeling of tiredness. - Increased urination: due to the diuretic component. - Flushing: transient warmth or redness of the skin.

Serious or Rare Side Effects: - Hyperkalemia: elevated blood potassium levels. - Acute kidney injury: sudden decline in renal function. - Severe hypotension: marked drop in blood pressure causing fainting. - Angio‑edema: swelling of lips, tongue or airway. - Hepatic dysfunction: abnormal liver enzyme elevations. - Blood dyscrasias: rare blood‑cell abnormalities.

Before initiating therapy, clinicians should assess patient history and monitor laboratory parameters. - Renal function: evaluate serum creatinine and eGFR, adjust if impaired. - Electrolytes: monitor potassium and sodium levels, especially with diuretic use. - Hepatic disease: use cautiously in patients with liver impairment. - Pregnancy: avoid use in pregnancy; teratogenic risk is associated with ARBs. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at below 25°C: keep tablets in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide may interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade can cause renal failure and hyperkalemia. - Potassium‑sparing diuretics or supplements: increase risk of hyperkalemia. - NSAIDs (high dose): may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase serum lithium levels, risking toxicity. - CYP3A4 inhibitors (e.g., clarithromycin): can raise amlodipine concentrations. - Antidiabetic agents: enhanced glucose‑lowering effect may require dose adjustment.